ClinicalTrials.gg
CompletedNCT04682288Updated Dec 8, 2021

Levofloxacin Ocular Implant for Ocular Surgery

A Phase 1 interventional study of Levofloxacin Ocular Implant in Cataract, sponsored by PolyActiva Pty Ltd. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-08.

Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
304th of 322
5 · median 100
Started
2021
with 21 others
Phase 1
10 of 456
1 open now
Registered
312th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 304th largest by enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2021, is one of 10 in phase 1, and was the 312th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

This is a multi center, open label, interventional study in one eye of 5 subjects scheduled for uncomplicated cataract surgery with administration of a single Levofloxacin Ocular Implant in the posterior sulcus of the surgical eye at the end of cataract surgery.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of cataract in the intent to treat eye
  • Endothelial cell density in the study eye of at least 2000 cells per mm2

Exclusion criteria

Exclusion Criteria:

  • history of ocular inflammation including, macular degeneration, uveitis, macular edema or corneal edema
  • recent surgery in the study eye
  • subjects receiving a glaucoma device in conjunction with cataract surgery
  • subjects with a compromised posterior capsule during surgery
  • corneal disease that prevents effective imaging of endothelium including Fuch's Dystrophy.
  • sensitivity to fluoroquinolones
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Levofloxacin Ocular Implant

    Biphasic levofloxacin antibiotic implant

    Drug: Levofloxacin Ocular Implant

Interventions

  • DrugLevofloxacin Ocular Implant

    Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.

06

What researchers measure

Primary outcomes

  1. Ocular Inflammation

    Change assessed according to Standardization of Uveitis Nomenclature (SUN) Grading Scale

    Time frame: 90 days

  2. Endothelial Cell Density

    Change in number of central corneal endothelial cells per mm2

    Time frame: 90 days

  3. Intraocular Pressure (IOP)

    Change in IOP measured by Goldmann applenation tonometry

    Time frame: 90 days

Secondary outcomes

  1. Administration procedure

    Number of actuation's required to expel implant

    Time frame: 1 week

07

Study locations

3 sites
  • Ophthalmology Consultants Ltd
    Saint Louis, Missouri 63131, United States
  • Carolina Cataract and Laser Centre
    Ladson, South Carolina 29456, United States
  • Melbourne Eye Specialists
    Fitzroy, Victoria 3065, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Oct 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2020
First posted
Dec 23, 2020
StartActual
Jan 4, 2021
Primary completionActual
Oct 14, 2021
CompletionActual
Oct 14, 2021
Last update
Dec 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04682288
Lead sponsor
PolyActiva Pty Ltd
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Jan 4, 2021
Primary completion
Oct 14, 2021
Completion
Oct 14, 2021
Last update
Dec 8, 2021

Study contacts

Joseph Gira, MD
principal investigator · Opthalmology Consultants Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion